LONGitudinal Multi-omics Phenotyping of KIDney Function Alteration
Observation of Alterations in Kidney Function, Immune System and Gut Mircobiota After Living Donor Kidney Transplantation
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Hendrik Bartolomaeus, MD
- Phone Number: +49 30 450 540 464
- Email: hendrik.bartolomaeus@charite.de
Study Locations
-
-
-
Berlin, Germany, 13125
- Recruiting
- Experimental and Clinical Research Center
-
Contact:
- Hendrik Bartolomaeus, MD
- Phone Number: +49 30 450 540 464
- Email: hendrik.bartolomaeus@charite.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Body-Mass-Index 18,5 - 34,9 kg/m2
- Planned living kidney donation / transplantation
Exclusion Criteria:
- Clinically relevant heart, lung, liver, and kidney diseases
- Postoperative phase
- Acute infections
- Vegan diet
- Change of body weight of more than 10% in the month prior to study entry
- Known drug or alcohol abuse
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Kidney Donor
Defined as a human individual donating a kidney
|
|
Kidney Recipient
Defined as a patient suffering from chronic kidney disease being the recipient of a kidney transplant
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fecal microbiome taxonomy (Shannon-Index)
Time Frame: Change from Baseline at 24 weeks
|
Measured by 16S amplicon sequencing
|
Change from Baseline at 24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional capacity of gut microbiota
Time Frame: Change from Baseline at 24 weeks
|
Measured by metagenome sequencing
|
Change from Baseline at 24 weeks
|
|
Frequency of circulating T-cell subtypes
Time Frame: Change from Baseline at 24 weeks
|
Measured by flow cytometry (%)
|
Change from Baseline at 24 weeks
|
|
Serum tryptophan metabolites concentration
Time Frame: Change from Baseline at 24 weeks
|
Measured by mass spectrometry
|
Change from Baseline at 24 weeks
|
|
Serum short-chain fatty acid concentration
Time Frame: Change from Baseline at 24 weeks
|
Measured by mass spectrometry
|
Change from Baseline at 24 weeks
|
|
Fecal tryptophan metabolites concentration
Time Frame: Change from Baseline at 24 weeks
|
Measured by mass spectrometry
|
Change from Baseline at 24 weeks
|
|
Fecal short-chain fatty acid concentration
Time Frame: Change from Baseline at 24 weeks
|
Measured by mass spectrometry
|
Change from Baseline at 24 weeks
|
|
Office systolic blood pressure
Time Frame: Change from Baseline at 24 weeks
|
Mean of five consecutive blood pressure measurements (mmHg)
|
Change from Baseline at 24 weeks
|
|
Office diastolic blood pressure
Time Frame: Change from Baseline at 24 weeks
|
Mean of five consecutive blood pressure measurements (mmHg)
|
Change from Baseline at 24 weeks
|
|
Body fat content
Time Frame: Change from Baseline at 24 weeks
|
Measured by bioelectrical impedance analysis (%)
|
Change from Baseline at 24 weeks
|
|
Fat free mass
Time Frame: Change from Baseline at 24 weeks
|
Measured by bioelectrical impedance analysis (%)
|
Change from Baseline at 24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Anja Mähler, PhD, Charite University, Berlin, Germany
- Principal Investigator: Nicola Wilck, MD, Charite University, Berlin, Germany
- Principal Investigator: Hendrik Bartolomaeus, MD, Charite University, Berlin, Germany
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LONGKID
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.